NIOX Group (NIOXL) Stock Overview

Engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. More details

NIOXL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	1/6

Rewards

Trading at 30.3% below our estimate of its fair value

Earnings are forecast to grow 34.15% per year

Risk Analysis

Profit margins (10.7%) are lower than last year (28.2%)

NIOXL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

NIOX Group Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for NIOX Group
Historical stock prices
Current Share Price	UK£0.72
52 Week High	UK£0.75
52 Week Low	UK£0.64
Beta	-0.16
1 Month Change	2.73%
3 Month Change	-5.04%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-76.91%

Recent updates

Shareholder Returns

	NIOXL	GB Medical Equipment	GB Market
7D	1.4%	1.7%	2.0%
1Y	n/a	15.2%	16.1%

Return vs Industry: Insufficient data to determine how NIOXL performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how NIOXL performed against the UK Market.

Price Volatility

Is NIOXL's price volatile compared to industry and market?
NIOXL volatility
NIOXL Average Weekly Movement	4.6%
Medical Equipment Industry Average Movement	4.5%
Market Average Movement	5.0%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: NIOXL has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine NIOXL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	91	Jonathan Emms	www.niox.com

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled Nitric Oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.

NIOX Group Plc Fundamentals Summary

How do NIOX Group's earnings and revenue compare to its market cap?
NIOXL fundamental statistics
Market cap	UK£301.71m
Earnings (TTM)	UK£4.90m
Revenue (TTM)	UK£46.00m

61.6x

P/E Ratio

6.6x

P/S Ratio

Is NIOXL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NIOXL income statement (TTM)
Revenue	UK£46.00m
Cost of Revenue	UK£13.30m
Gross Profit	UK£32.70m
Other Expenses	UK£27.80m
Earnings	UK£4.90m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.012
Gross Margin	71.09%
Net Profit Margin	10.65%
Debt/Equity Ratio	0%

How did NIOXL perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

105%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/27 03:55
End of Day Share Price	2025/11/27 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NIOX Group Plc is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julie Simmonds	Canaccord Genuity
Kane Slutzkin	Deutsche Bank
Jens Lindqvist	Investec Bank plc (UK)

NIOX Group PlcBATS-CHIXE:NIOXL Stock Report